• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Nuvation Bio Inc.

    6/26/26 5:28:28 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVB alert in real time by email
    FWP 1 d21520dfwp.htm FWP FWP

    Filed Pursuant to Rule 433

    Registration No. 333-285621

    Relating to the

    Preliminary Prospectus Supplement

    dated June 25, 2026

    (To Prospectus dated March 6, 2025)

    PRICING TERM SHEET

    June 25, 2026

    Nuvation Bio Inc.

    Offering of

    $250,000,000 0.75% Convertible Senior Notes Due 2032

    The information in this pricing term sheet supplements Nuvation Bio Inc.’s preliminary prospectus supplement, dated June 25, 2026 (the “Preliminary Prospectus Supplement”), and the accompanying prospectus, dated March 6, 2025, each filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”). This pricing term sheet supersedes the information in the Preliminary Prospectus Supplement to the extent inconsistent with the information in the Preliminary Prospectus Supplement. In all other respects, this pricing term sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement, including all other documents incorporated by reference therein. References to “we,” “our” and “us” refer to Nuvation Bio Inc. and not to its consolidated subsidiaries and references to “Class A common stock” refer to our Class A common stock, par value $0.0001 per share. Terms used herein but not defined herein shall have the respective meanings as set forth in the Preliminary Prospectus Supplement. All references to dollar amounts are references to U.S. dollars. Nuvation Bio Inc. has increased the size of the offering of the notes from the previously announced offering size of $200,000,000. The final prospectus supplement relating to the offering will reflect conforming changes relating to such increase in the size of the offering.

     

    Issuer:    Nuvation Bio Inc.
    Ticker/Exchange for Our Class A Common Stock:    “NUVB” / the New York Stock Exchange.
    Securities:    0.75% Convertible Senior Notes due 2032 (the “notes”).
    Offering Size:    $250,000,000 aggregate principal amount of notes (plus up to an additional $37,500,000 aggregate principal amount of notes pursuant to the underwriters’ over-allotment option).
    Offering Price:    100% of principal amount per note.
    Denominations:    $1,000 and integral multiples of $1,000 in excess thereof.
    Underwriting Discount:    3.0% of the principal amount of the notes, and $7,500,000 in the aggregate (or $8,625,000 in the aggregate, if the underwriters exercise their over-allotment option in full).
    Ranking:    Senior unsecured.
    Maturity:    July 1, 2032, unless earlier converted, redeemed or repurchased.
    Redemption at Our Option:    We may not redeem the notes prior to July 6, 2029. We may redeem for cash all or any portion of the notes (subject to the partial redemption limitation described below), at our option, on a redemption date on or after July 6, 2029 if the last reported sale price of our Class A common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the related notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If we redeem less than all the outstanding notes, at least $75.0 million aggregate principal amount of notes must be outstanding and not subject to redemption as of, and after giving effect to, delivery of the relevant notice of redemption. No “sinking fund” is provided for the notes, which means that we are not required to redeem or retire the notes periodically. See the caption “Description of Notes–Optional Redemption” in the Preliminary Prospectus Supplement.

     

    1


    Fundamental Change:    If we undergo a “fundamental change” (as defined in the Preliminary Prospectus Supplement under the caption “Description of Notes–Fundamental Change Permits Holders to Require Us to Repurchase Notes”), then, subject to certain conditions and except as described in the Preliminary Prospectus Supplement, holders may require us to repurchase for cash all or any portion of their notes in principal amounts of $1,000 or an integral multiple thereof. The fundamental change repurchase price will be equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. See the caption “Description of Notes-Fundamental Change Permits Holders to Require Us to Repurchase Notes” in the Preliminary Prospectus Supplement.
    Interest and Interest Payment Dates:    0.75% per year.
       Interest will accrue from June 30, 2026 and will be payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2027.
    Interest Record Dates:    December 15 and June 15 of each year (whether or not a business day), immediately preceding any January 1 or July 1 interest payment date, as the case may be.
    Last Reported Sale Price of Our Class A Common Stock on the New York Stock Exchange on June 25, 2026:    $5.81 per share.
    Initial Conversion Rate:    127.4941 shares of our Class A common stock per $1,000 principal amount of the notes.
    Initial Conversion Price:    Approximately $7.84 per share of our Class A common stock.
    Conversion Premium:    Approximately 35.0% above the last reported sale price of our Class A common stock on the New York Stock Exchange on June 25, 2026.
    Settlement Method:    Cash, shares of our Class A common stock or a combination of cash and shares of our Class A common stock, at our election, as described in the Preliminary Prospectus Supplement.
    Joint Book-Running Managers:   

    Jefferies LLC

    Citigroup Global Markets Inc.

     

    2


       Cantor Fitzgerald & Co.
    Bookrunner:    RBC Capital Markets, LLC
    Pricing Date:    June 25, 2026.
    Trade Date:    June 26, 2026.
    Expected Settlement Date:    June 30, 2026.
       We expect that delivery of the notes will be made to investors in book-entry form through The Depository Trust Company on or about June 30, 2026, which will be the second business day following the Trade Date (this settlement cycle being referred to as “T+2”). Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the business day preceding the Expected Settlement Date will be required, by virtue of the fact that the notes initially will settle T+2, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to the business day preceding the Expected Settlement Date should consult their own advisors.
    CUSIP Number:    67080N AA9.
    ISIN:    US67080NAA90.
    Listing:    None.
    Use of Proceeds:   

    We estimate that the net proceeds from the offering will be approximately $241.2 million (or approximately $277.6 million if the underwriters’ over-allotment option is exercised in full), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.

     

    We expect to use the net proceeds from the offering (i) to pay the $14.9 million cost of the capped call transactions described under the caption “Description of Capped Call Transactions” in the Preliminary Prospectus Supplement, (ii) to repay in full all obligations under our senior secured loan agreement, and (iii) for general corporate purposes, which may include working capital, operating expenses, capital expenditures and general and administrative expenses. See the caption “Use of Proceeds” in the Preliminary Prospectus Supplement.

    Cap Price:    The cap price of the capped call transactions relating to the notes will initially be $10.4580, which represents a premium of 80.0% over the last reported sale price of our Class A common stock on the New York Stock Exchange on June 25, 2026, and is subject to certain adjustments under the terms of the capped call transactions. See the caption “Description of Capped Call Transactions” in the Preliminary Prospectus Supplement.

     

    3


    Description of Notes-Conversion Rights-Increase in Conversion Rate upon Conversion upon a Make-Whole

    Fundamental Change or Notice of Redemption

    Holders who convert their notes in connection with a make-whole fundamental change (as defined in the Preliminary Prospectus Supplement) occurring prior to the maturity date or convert their notes called for redemption (or deemed called for redemption) during the related redemption period (as defined in the Preliminary Prospectus Supplement) may be entitled to an increase in the conversion rate for the notes so surrendered for conversion as set forth in the Preliminary Prospectus Supplement under the caption “Description of Notes-Conversion Rights-Increase in Conversion Rate upon Conversion upon a Make-Whole Fundamental Change or Notice of Redemption.”

    The following table sets forth the number of additional shares by which the conversion rate will be increased per $1,000 principal amount of notes for each stock price and effective date set forth below:

     

         Stock Price  

    Effective Date

       $5.81      $6.50      $7.84      $9.00      $10.20      $15.00      $20.00      $30.00      $40.00      $50.00  

    June 30, 2026

         44.6229        36.7062        26.1148        20.0678        15.6392        6.7053        3.1890        0.8020        0.1480        0.0000  

    July 1, 2027

         44.6229        36.7062        26.1148        19.9978        15.3804        6.2827        2.8505        0.6410        0.0898        0.0000  

    July 1, 2028

         44.6229        36.7062        26.1148        19.4756        14.6971        5.5913        2.3645        0.4450        0.0298        0.0000  

    July 1, 2029

         44.6229        36.7062        25.1939        18.2189        13.3510        4.5373        1.7090        0.2300        0.0010        0.0000  

    July 1, 2030

         44.6229        36.7062        23.0217        15.8267        11.0029        3.0500        0.9245        0.0487        0.0000        0.0000  

    July 1, 2031

         44.6229        33.4646        18.4158        11.2111        6.8618        1.1760        0.2020        0.0000        0.0000        0.0000  

    July 1, 2032

         44.6229        26.3523        0.0574        0.0000        0.0000        0.0000        0.0000        0.0000        0.0000        0.0000  

    The exact stock prices and effective dates may not be set forth in the table above, in which case:

     

      •  

    If the stock price is between two stock prices in the table or the effective date is between two effective dates in the table, the number of additional shares by which the conversion rate will be increased will be determined by a straight-line interpolation between the number of additional shares set forth for the higher and lower stock prices and the earlier and later effective dates, as applicable, based on a 365- or 366-day year, as applicable.

     

      •  

    If the stock price is greater than $50.00 per share (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table above as described in the Preliminary Prospectus Supplement), no additional shares will be added to the conversion rate.

     

      •  

    If the stock price is less than $5.81 per share (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table above as described in the Preliminary Prospectus Supplement), no additional shares will be added to the conversion rate.

    Notwithstanding the foregoing, in no event will the conversion rate per $1,000 principal amount of notes exceed 172.1170 shares of our Class A common stock, subject to adjustment in the same manner as the conversion rate as set forth in the Preliminary Prospectus Supplement under the caption “Description of Notes–Conversion Rights–Conversion Rate Adjustments.”

    We have filed a registration statement (including a prospectus) and the Preliminary Prospectus Supplement with the SEC for the offering to which this communication relates. Before you invest, you should read the Preliminary Prospectus Supplement and the prospectus in that registration statement and other documents we have filed with the SEC for more complete information about us and the offering. You may get these documents free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, we, any underwriter or any dealer participating in the offering will arrange to send you the Preliminary Prospectus Supplement (or, when available, the final prospectus supplement) and the accompanying prospectus upon request to Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; Citigroup Global Markets Inc., c/o

     

    4


    Broadridge Financial Solutions 1155 Long Island Avenue, Edgewood, NY 11717, by phone at 1-800-831-9146; Cantor Fitzgerald & Co. by mail at Attention: Capital Markets, 110 East 59th Street, New York, NY 10022 or by email at prospectus@cantor.com; or RBC Capital Markets, LLC, Attn: Equity Capital Markets, 200 Vesey Street, 8th floor, New York, NY 10281, by telephone at 877-822-4089 or by email at equityprospectus@rbccm.com.

    The information in this pricing term sheet is not a complete description of the notes or the offering. You should rely only on the information contained or incorporated by reference in the Preliminary Prospectus Supplement and the accompanying prospectus, as supplemented by this pricing term sheet, in making an investment decision with respect to the notes.

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

     

    5

    Get the next $NUVB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVB

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    11/19/2025$12.00Buy
    B. Riley Securities
    9/30/2025$10.00Buy
    Jefferies
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    3/27/2024$1.40 → $10.00Hold → Buy
    Jefferies
    3/26/2024$5.00Neutral → Buy
    BTIG Research
    1/6/2023$5.00 → $2.00Buy → Hold
    Jefferies
    8/2/2022$8.00 → $2.50Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $NUVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Nuvation Bio

    Truist initiated coverage of Nuvation Bio with a rating of Buy

    11/24/25 8:30:57 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Nuvation Bio with a new price target

    B. Riley Securities initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $12.00

    11/19/25 8:57:29 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Nuvation Bio with a new price target

    Jefferies initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $10.00

    9/30/25 8:57:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mashal Robert bought $118,250 worth of shares (25,000 units at $4.73) (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/11/26 8:02:51 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:15 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:21 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    SEC Filings

    View All

    SEC Form FWP filed by Nuvation Bio Inc.

    FWP - Nuvation Bio Inc. (0001811063) (Subject)

    6/26/26 5:28:28 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Nuvation Bio Inc.

    424B5 - Nuvation Bio Inc. (0001811063) (Filer)

    6/25/26 7:08:03 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Nuvation Bio Inc.

    144 - Nuvation Bio Inc. (0001811063) (Subject)

    6/23/26 4:28:18 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

    NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the "Notes"). The aggregate principal amount of the Offering was increased from the previously announced offering size of $200.0 million. The sale of the Notes to the underwriters is expected to close on June 30, 2026, subject to customary closing conditions. Nuvation Bio also granted the underwriters of the Notes a right to purchase, exercisable within 30 days

    6/25/26 11:58:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Announces Proposed Convertible Senior Notes Offering

    NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the "Notes") in an underwritten offering (the "Offering"). Nuvation Bio also intends to grant the underwriters of the Notes a right to purchase, exercisable within 30 days of the date of the prospectus supplement relating to the Offering, up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if

    6/25/26 7:00:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio to Present at the Jefferies Global Healthcare Conference

    NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:55 a.m. ET in New York, NY. A live webcast of the fireside chat will be available on the Investor Relations section of the Nuvation Bi

    5/27/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF PEOPLE OFFICER Markel Stacy exercised 125,000 shares at a strike of $1.83 and sold $753,188 worth of shares (125,000 units at $6.03) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/24/26 7:09:49 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF REGULATORY OFFICER Wentworth Kerry exercised 63,000 shares at a strike of $2.93 and sold $379,191 worth of shares (63,000 units at $6.02) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/24/26 7:07:53 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sauvage Philippe exercised 47,668 shares at a strike of $2.17 and sold $286,370 worth of shares (47,668 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/24/26 7:07:16 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Financials

    Live finance-specific insights

    View All

    Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

    Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-naïve, highlighting continued momentum in the first-line settingPresented newly updated clinical data demonstrating IBTROZI's impressive durability of response and progression-free survival in TKI-naïve and TKI-pretreated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) at AACR 2026 Announced acquisition of Japan rights to safusidenib from Daiichi Sankyo, enabling global development and commercialization of promising investigational medicineStrong balance sheet with

    5/4/26 4:10:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

    NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (

    4/20/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and JapanPublished positive Phase 2 study results for safusidenib demonstrating durable responses for the treatment of grade 2 IDH1-mutant gliomaStrong balance sheet with cash, cash equivalents, and marketable securities of $529.2 million as of December 31, 2025Company to host a conference call today at 4:30 pm ETNEW YORK, March 2, 2026 /PRNewswire/ -- Nuva

    3/2/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

    Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

    10/7/24 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

    Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

    5/14/24 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

    Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

    3/28/24 8:00:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

    SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

    11/12/24 10:32:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

    SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

    10/18/24 4:15:55 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Nuvation Bio Inc.

    SC 13D - Nuvation Bio Inc. (0001811063) (Subject)

    9/10/24 4:51:38 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care